1,263 reports of this reaction
4.4% of all POLYETHYLENE GLYCOL 400 reports
#2 most reported adverse reaction
INCORRECT PRODUCT ADMINISTRATION DURATION is the #2 most commonly reported adverse reaction for POLYETHYLENE GLYCOL 400, manufactured by Bausch & Lomb Incorporated. There are 1,263 FDA adverse event reports linking POLYETHYLENE GLYCOL 400 to INCORRECT PRODUCT ADMINISTRATION DURATION. This represents approximately 4.4% of all 28,955 adverse event reports for this drug.
Patients taking POLYETHYLENE GLYCOL 400 who experience incorrect product administration duration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT PRODUCT ADMINISTRATION DURATION is moderately reported among POLYETHYLENE GLYCOL 400 users, representing a notable but not dominant share of adverse events.
In addition to incorrect product administration duration, the following adverse reactions have been reported for POLYETHYLENE GLYCOL 400:
The following drugs have also been linked to incorrect product administration duration in FDA adverse event reports:
INCORRECT PRODUCT ADMINISTRATION DURATION has been reported as an adverse event in 1,263 FDA reports for POLYETHYLENE GLYCOL 400. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT PRODUCT ADMINISTRATION DURATION accounts for approximately 4.4% of all adverse event reports for POLYETHYLENE GLYCOL 400, making it one of the most commonly reported side effect.
If you experience incorrect product administration duration while taking POLYETHYLENE GLYCOL 400, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.